Table of Contents

    Topic review

    Epigenetics of Aging

    Subjects: Genetics
    View times: 7
    Submitted by: Dominik Saul


    Aging represents the multifactorial decline in physiological function of every living organism. Over the past decades, several hallmarks of aging have been defined, including epigenetic deregulation. Indeed, multiple epigenetic events were found altered across different species during aging. Epigenetic changes directly contributing to aging and aging-related diseases include the accumulation of histone variants, changes in chromatin accessibility, loss of histones and heterochromatin, aberrant histone modifications, and deregulated expression/activity of miRNAs. As a consequence, cellular processes are affected, which results in the development or progression of several human pathologies, including cancer, diabetes, osteoporosis, and neurodegenerative disorders.

    1. Introduction

    Aging is a multifactorial biological process of declining physiological functions increasing the susceptibility to aging-related chronic diseases, such as cancer, metabolic, cardiovascular, musculoskeletal, as well as neurodegenerative diseases [1]. Numerous studies have focused on the decipherment of the hallmarks of aging in order to identify potential therapeutic targets to mitigate the aging process. Hallmarks of aging include stem cell exhaustion, altered intercellular communication, senescence, genomic instability, and epigenetic deregulation [2].

    Epigenetics refers to reversible heritable mechanisms, which can affect gene expression without underlying changes in DNA sequences, but rather via chromatin modifications. Eukaryotic chromatin is a highly condensed structure containing repeating structural subunits, the nucleosomes. Each nucleosome consists of a histone octamer assembled of two copies of each histone (H2A, H2B, H3, and H4, as well as histone variants, such as macroH2A, H3.3 and H2A.Z), wrapped around by 147 base pairs of DNA [3][4]. Each core histone possesses histone-fold domains serving for the interaction of the histones and N-terminal histone-tails. These tails can be subjected to post-translational modifications, which frequently affect gene expression. These modifications include, for instance, histone acetylation, methylation, phosphorylation and ubiquitination [5].

    Epigenetics is a rapidly evolving research field and there is a profound interest in therapies targeting epigenetic as well as aging-related processes. In this study, we focus on aging-associated epigenetic regulatory mechanisms and highlight their implications in aging-related diseases.

    2. Epigenetics of Aging and Aging-Related Diseases

    2.1. Epigenetic Changes in Aging

    2.1.1. Histone and Heterochromatin Loss

    The DNA is organized into complex three-dimensional structures; however, for gene transcription, the DNA sequence has to be accessible to key regulators, such as transcription factors and RNA polymerases. Besides chromatin remodeling, which results in the rearrangement of chromatin structures, the global number of histones defines DNA accessibility [6]. In fact, the loss of histones during cellular aging is one of the key observations from simple eukaryotic models, including yeast, to mice and humans. In a micrococcal nuclease-DNA sequencing (MNase-seq) approach detecting protein-unbound DNA regions in young and old Saccharomyces cerevisiae, a nucleosome loss of approximately 50% was detected. As a consequence, global transcription levels were highly upregulated in aged cells [7]. Similarly, aging human fibroblasts grown in vitro showed a replication-associated reduction in histone biosynthesis and quiescent satellite cells displayed decreased histone expression [8][9].

    Reduced synthesis of histones together with changes in chromatin structure leads to a global loss of constitutive heterochromatin, one of the earliest models associated with aging. Heterochromatin loss, the transition from highly condensed to tightly packed chromatin structures, during aging has been observed across many species. As a consequence, modified chromatin architecture, the de-repression of silenced genes and global gene expression changes can occur [10].

    2.1.2. Histone Variants

    Besides the loss of histones, the exchange of canonical histones (H2A, H2B, H3, and H4) with histone variants was observed in aging organisms. These histone variants display distinct primary sequence and properties compared to canonical histones, thereby regulating gene transcription programs. Various aging-related studies evaluating histone variants in murine, primate and human cells implicate a high enrichment of macroH2A (mH2A), H3.3 and H2A.Z. In general, the incorporation of histone variants into the chromatin can be replication-coupled or replication-independent. The replication-coupled process results in a genome-wide incorporation of new nucleosomes into gaps between pre-existing nucleosomes. In contrast, the replication-independent addition of nucleosomes or subunits occurs locally. Thus, during the replication-independent process, histone variants can replace canonical histones, thereby potentially altering gene expression programs [11][12]. The mH2A isoforms are characterized by the presence of a C-terminal 30 kDa non-histone macro domain [13][14], and were shown to facilitate the activation of transcription factors during differentiation processes [13] and the prevention of the reactivation of pluripotency-associated genes [15]. Notably, human fibroblasts undergoing replicative senescence in vitro as well as several tissues isolated from aging mice and primates displayed an enrichment in mH2A levels [16].

    Another example is the H3 variant H3.3, which differs from the canonical form by only four amino acids. It was shown to be incorporated only in a replication-independent manner and to be enriched in transcriptionally active chromatin regions. Recent aging studies in mice revealed that H3.3 accumulates in various tissues during aging and that the canonical isoforms have been almost completely replaced by this histone variant by the age of 18 months [17]. Moreover, H3.3 was linked to aging processes in Caenorhabditis elegans. Here, the deletion of H3.3 resulted in profound transcription changes of longevity-associated genes and in decreased survival [18]. Similar results were found when analyzing postmortem human brains where H3.3 levels gradually increased over the first decade of life. In individuals who were 14 to 72 years old, H3.3 amounts remained stable [19].

    2.1.3. DNA Methylation

    Besides histone methylation, DNA can be directly methylated through the covalent linkage of a methyl group to the fifth position of the cytosine ring to generate 5-methylcytosine (5mC). This modification is mainly present in DNA regions rich in cytosine-phospho-guanine (CpG) dinucleotides. While there is extensive evidence that DNA methylation at promoter regions is associated with gene silencing, the decipherment of the function of gene body methylation is still ongoing [20][21][22]. The repression of transcription due to covalent addition of methyl groups onto the DNA can be mediated by interfering with the site-specific binding of transcription factors or by the recruitment of methyl-CpG-binding domain proteins [23][24]. The transfer of this heritable epigenetic mark is mediated by DNA methyltransferases (DNMTs) including DNMT1, DNMT2, DNMT3A, DNMT3B, and DNMT3L. While DNMT1 has a maintenance function, the de novo establishment of DNA methylation is exerted by DNMT3A and DNMT3B alone or in a complex with DNMT3L [25][26].

    The conversion of 5mC to the unmodified state is thought to be mediated in an “active”, enzyme-dependent or in a “passive” demethylation process. The family of Ten Eleven Translocation (TET) proteins, TET1, TET2, and TET3, are able to erase DNA methylation in an “active” stepwise process [27][28]. These factors catalyze the oxidation of 5-methylcytosine (5mC) to the intermediates 5-hydroxymethylcytosine (5hmC), 5-formylcytosine (5fC), and 5-carboxylcytosine (5caC). After the recognition of 5fC and 5caC by the Thymine DNA Glycosylase (TDG), the oxidized cytosine base is excised. Finally, this abasic site will be recognized and replaced by an unmodified cytosine residue by Base Excision Repair (BER). During “passive” DNA demethylation, 5-methylcytosine is diluted in a replication-dependent process during cell division [29][30]. Interestingly, it has been demonstrated that a high abundance of 5hmC represses DNMT1 activity by 60-fold, suggesting a role of TET-mediated induction of “passive” demethylation [31].

    While methylation-associated control of gene expression pattern is essential for mammalian development and further cellular processes, it was thought to be dispensable in several organisms such as Caenorhabditis elegans and Drosophila melanogaster [32]. Recent studies describe the methylation of exocyclic NH2 groups at the sixth position of the purine ring in adenines (6 mA) in C. elegans, which is thought to be regulated through the DNA demethylase NMAD-1 and the DNA methyltransferase DAMT1 [33]. In addition, there is emerging knowledge on species- and life cycle-dependent 5mC levels among the genomes of the members of genus Drosophila [34].

    While it has been known for several decades that DNA methylation can regulate gene expression patterns, biological consequences are still not fully investigated. Generally, it has been described that CpGs at promoter regions display hypermethylation while other CpGs undergo hypomethylation during aging [35]. Remarkably, two large-scale studies significantly contributed to the understanding of the relevance of DNA methylation pattern during aging. The authors identified 353 and 71 CpG sites, respectively [36][37], which were differentially methylated during aging and, therefore, can serve as reliable age predictors in human tissues. In fact, this “epigenetic clock” displays a robust correlation to age (r = 0.96 and r = 0.91, respectively) with minor deviations from the calendar age of analyzed individuals (3.6 and 4.9 years, respectively). In a comparative study evaluating the robustness of biological age predictors (i.e., epigenetic clock, telomere length, composite biomarker predictors, as well as transcriptome-, proteome- and metabolome-based predictors), the epigenetic clock was suggested to be the most reliable readout. However, further confirmatory studies will be needed to additionally evaluate the predictive values of these biological hallmarks of aging [38].

    2.2. Epigenetic Changes in Aging-Related Diseases

    Epigenetic discoveries helped to lay the foundation for a deeper perception of multiple diseases. For instance, epigenetic events can contribute to the “hallmarks of cancer” (i.e., chromatin structure affecting cellular identity or methylation patterns leading to evasion from apoptosis), having led to a revised “hallmark” definition [39][40]. Here, we summarize the latest epigenetic discoveries in a selected range of medical conditions with a focus on certain cancer entities, inflammation, musculoskeletal disorders, neurodegenerative diseases, and nutritional diseases.

    2.2.1. Cancer

    DNA methylation patterns and miRNAs can influence chromatin state regulation [41][42]. In cancer development, the degenerated cell may unrestrictedly proliferate as a consequence of DNA hypermethylation or deregulation of epigenetic modifiers. Methylation of the promotor region of the tumor suppressor genes, for instance VHL, was associated with angiogenesis, leading to an enhanced supply for the tumor environment. Cell death was shown to be impaired by epigenetic modification of apoptotic or cell cycle key players including CDKN2A, hypermethylation of which leads to a loss-of-function gene in numerous cancers [41][42][43]. Here, we focus on two entities to exemplarily demonstrate age-related shifts and deregulations associated with leukemia and colorectal cancer.

    2.2.2. Inflammation

    It is broadly accepted that inflammation is a common event during aging, referred to as “inflamm-aging” [44]. This process is a underlying condition of several diseases such as sarcopenia, osteoarthritis, and cancer [45]. A hallmark of these processes is an increase in Tumor Necrosis Factor alpha (TNFα) levels. DNA methylation and histone acetylation modify the promoter region of TNFα [46]. The TNFα gene itself does not contain a classical CpG island, however, its promoter and first exon were described to be rich in CpG sequences [46]. Accordingly, methylation on these gene regions has been described to negatively regulate TNFα expression levels [47]. Wang et al. demonstrated in porcine spleens by bisulfite sequencing PCR and qPCR that the TNFα promoter region was increasingly methylated with age, correlating with decreased mRNA expression [48].

    Similarly, NF-κB mediates acute, as well as chronic inflammation, and is proposed as one of the key regulators of aging. Via its transcriptional activity, the NF-κB family induces the expression of cytokines and genes associated with apoptosis and senescence as described elsewhere [49]. NF-κB levels can be regulated by various epigenetic mechanisms including the acetylation of histone H3 via the H3 lysine 4 methyltransferase SET7/9 [50] which represents a potential targeting strategy [47]. The link to aging has been validated in the skin where C57BL/6 mice exposed to UVB light for 16 days displayed accelerated aging of the skin via NF-κB activation through the mTORC2 pathway. The post-translational modification of the p65 member of NF-κB at Ser536 enhanced NF-κB activity via increased DNA binding activity. The same phenomenon was detected in physiological aged skin of these mice, demonstrating an accelerated inflammatory status in physiological as pathological (skin) aging [51][52].

    Another epigenetic modification, which has been demonstrated to regulate NF-κB activity during inflammation, is the monoubiquitination at lysine 120 of histone H2B (H2Bub1). This monoubiquitination is performed by the RNF20/RNF40 E3 ligase complex and leads to increased chromatin accessibility. This results in eased passage of RNA Polymerase II and highly active transcriptional elongation [53]. Recently, it has been demonstrated that the monoubiquitination of histone H2B regulates NF-κB signaling in intestinal inflammation. However, the function of H2Bub1 in animal models for colitis remains inconclusive [54][55].

    In general, the transformation from chronic inflammation to cancer can be promoted via DNA methylation, histone modifications, chromatin remodeling and noncoding RNA regulation, upon which the most important pathways are NF-κB- and STAT3-related [56][57]. The phosphorylation of Tyr705, Ser727, and Ser727 are known to positively activate transcriptional activity of STAT3 [57][58]. One downstream target of this signaling pathway is interleukin-6, which has been shown to be repressed via treatment with the DNMT1 inhibitor 5-azadeoxycytidine (5-AzaC) [56]. MicroRNAs are further key regulators of inflammatory responses and inflamed tissues are characterized by downregulation of TET gene expression due to the upregulation of TET-targeting miRNAs (e.g., MiR20a, MiR26B, MiR29C, Let-7 microRNA) [59][60].

    Interestingly, the “epigenetic clock” concept of Horvath, has been demonstrated to be very accurate when methylation levels of CpG sites from white blood cells, the central regulators of immune response, were used [61][62][63]. These methylation levels were even able to predict mortality [64]. Despite a loss of T-cell diversity in old age, an exhausted/senescent CD8+ T cell population increases with age, possibly giving rise to associated diseases [65][66][67][68][69].

    Excessive inflammatory response, immunosenescence, and autoimmunity outline the other detrimental side of the inflammatory spectrum. The identification of hypomethylated apoptosis-related genes in naïve CD4+ T cells led to the definition of an evolving autoimmune epigenotype [70][71][72]. Accordingly, in chronic nonbacterial osteomyelitis, a reduced expression of immunoregulatory cytokines (IL-10, IL-19) was centrally involved. The authors demonstrated in monocytes from chronic recurrent multifocal osteomyelitis patients that an altered SP1 activation negatively affected IL10 and IL19 expression. Mechanistically, the reduced phosphorylation of histone 3 serine 10 (H3S10P) and impaired SP1 phosphorylation at the IL10 and IL19 promoter regions impaired IL10 expression. This causes an imbalance towards proinflammatory cytokines (compared to anti-inflammatory IL-10 and IL-19), leading to inflammatory bone loss [73]. Similar reductions of H3S1p levels have been identified in hippocampi of aged mice by Wu et al. [74], which were associated with the inflammation-related decline in spatial learning and memory.

    2.2.3. Osteoporosis

    Osteoporosis is tightly linked to aging via epigenetic changes in mesenchymal stem cells (MSCs) [75]. Physiologically, the Osterix promoter was shown to entail enriched levels of H3Ac/H3K4me3 and reduced levels of H3K9me3/H3K27me3, inducing the differentiation of MSCs into osteoblasts to mediate skeletal tissue homeostasis [75][76]. Among the key transcription factors for osteogenesis are HOX and RUNX2, both of which are hypermethylated in aged MSCs [77]. Bork and colleagues demonstrated in MSCs isolated from bone marrow aspirates from young and old human donors that long-term cell culture and regular aging result in similar epigenetic profiles. HOXA (2,5,6) and RUNX2, transcription factors involved in osteoblast differentiation, were the most prominent among genes hypermethylated during aging which leading to decreased gene expression and age-related bone loss [78].

    To prevent the hypermethylation of RUNX2, the transcriptional activation of the methyltransferase DNMT1 can be inhibited via 5-AzaC treatment. As expected, 5-AzaC leads to a hypomethylation of genomic DNA resulting in increased expression of RUNX2, Osteocalcin (OCN) and Osterix (OSX). The beneficial effect of 5-AzaC was supported by Zhou et al. in cell culture experiments using MSCs. Besides a global reduction in methylation levels, an increase in osteogenic gene expression was detected as demonstrated via enhanced alkaline phosphatase (ALP) activity and, subsequently, aggrandized mineralization [77].

    It was shown in human bone marrow stromal cells (BMSCs) that in osteoporosis the number of clonogenic BMSCs was reduced, corresponding to decreased levels of Tet1 and Tet2, factors, which are able to erase DNA methylation. During normal osteogenesis, TET1 and TET2 levels were enhanced with an increased binding to the Osterix promoter [75][79]. Yang et al. detected an osteopenic phenotype and decreased Runx2 expression in Tet1−/−Prx1creTet2fl/fl mice. After the authors demonstrated that the use of siRNAs against TET1 and TET2 led to reduced stem cell properties in bone marrow MSCs (BMMSCs), they found via RNA-seq and qPCR in their mouse model that miRNAs targeting Runx2 gene expression were significantly higher in the knockout mice and a treatment with mimics of these miRNAs increased Runx2 expression in BMMSCs. The authors used chromatin immunoprecipitation (ChIP)-qPCR to demonstrate that TET1 and TET2 directly bind to the CpG island of the P2rX7 promoter, a gene which has been linked to exosome release in earlier studies. After a depletion of Tet1 and Tet2, the subsequent methylation led to impaired self-renewal and differentiation potential on the stem cell level in the bone marrow, thus leading to an osteopenic phenotype [80]. Rising evidence shows a broad involvement of several miRNAs in osteoporosis, such as miR-297a-5p, miR-297b-5p, and miR-297c-5p. These are accumulating intracellularly, inhibiting RUNX2 expression, and thereby promoting an osteoporotic phenotype. This TET/P2rX7/RUNX2 cascade may serve as a target for novel therapeutic approaches [80][81]. Again, the link of Tet1/2 to aging has been made by Gontier et al. in the mouse brain, where a Tet2 reduction was detected in the hippocampi of aged mice, and the application of high-titer lentivirus encoding for Tet2 shRNA in young adult mice caused deficits in short-term and long-term learning [82].

    Mechanistically, an imbalance between histone modifications of osteogenic and adipogenic genes was proposed as an underlying mechanism of the development of musculoskeletal diseases. For instance, HDAC3 promotes osteogenesis and inhibits lipogenesis, while EZH2 and HDAC6 show opposite effects [77][83]. In bone marrow aspirates from human adults, it was demonstrated via retroviral-mediated enforced Ezh2 expression in MSCs that the differentiation potential into adipocytes was higher compared to vector control cells, along with reduced Runx2 transcription. Subsequent siRNA-mediated EZH2 depletion led to enhanced RUNX2 expression. Using ChIP-qPCR, the authors demonstrated that enforced EZH2 expression in MSCs resulted in increased H3K27me3 on transcriptional start sites of RUNX2, leading to a suppression of osteogenesis and marking EZH2 as positive regulator of adipogenesis and negative regulator of osteogenesis [83][84][85][86][87]. In another study, age-related bone loss was found linked to an increase in EZH2. In osteoporotic mice, Jing et al. detected via ChIP-qPCR that EZH2 was enriched at promoters of Wnt pathway members in BMSCs and a knockdown of EZH2 decreased H3K27me3 occupancy on these factors enhancing the Runx2 and Osterix expression and subsequently osteogenic differentiation. Accordingly, the authors suggested the H3K27me3 inhibitor DZNep as a potential therapeutic substance for anti-osteoporotic treatment [84].

    This translation of epigenetic discoveries into the clinic has already been established for several years. In fact, bisphosphonates (increasing MiR191c-5p and miR-497-5p) and monoclonal antibodies, such as denosumab, regulate—among others—DNA methyltransferases, histone acetylases, deacetalyses, and other key factors associated with detrimental epigenetic alterations [85][86][87].

    The entry is from 10.3390/ijms22010401


    1. Kennedy, B.K.; Berger, S.L.; Brunet, A.; Campisi, J.; Cuervo, A.M.; Epel, E.S.; Franceschi, C.; Lithgow, G.J.; Morimoto, R.I.; Pessin, J.E.; et al. Geroscience: Linking aging to chronic disease. Cell 2014, 159, 709–713.
    2. López-Otín, C.; Blasco, M.A.; Partridge, L.; Serrano, M.; Kroemer, G. The hallmarks of aging. Cell 2013, 153, 1194–1217.
    3. Luger, K.; Mäder, A.W.; Richmond, R.K.; Sargent, D.F.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 1997, 389, 251–260.
    4. Richmond, T.J.; Davey, C.A. The structure of DNA in the nucleosome core. Nature 2003, 423, 145–150.
    5. Torres, I.O.; Fujimori, D.G. Functional coupling between writers, erasers and readers of histone and DNA methylation. Curr. Opin. Struct. Biol. 2015, 35, 68–75.
    6. Zhang, W.; Qu, J.; Liu, G.-H.; Belmonte, J.C.I. The ageing epigenome and its rejuvenation. Nat. Rev. Mol. Cell Biol. 2020, 21, 137–150.
    7. Hu, Z.; Chen, K.; Xia, Z.; Chavez, M.; Pal, S.; Seol, J.-H.; Chen, C.-C.; Li, W.; Tyler, J.K. Nucleosome loss leads to global transcriptional up-regulation and genomic instability during yeast aging. Genes Dev. 2014, 28, 396–408.
    8. Liu, L.; Cheung, T.H.; Charville, G.W.; Hurgo, B.M.C.; Leavitt, T.; Shih, J.; Brunet, A.; Rando, T.A. Chromatin modifications as determinants of muscle stem cell quiescence and chronological aging. Cell Rep. 2013, 4, 189–204.
    9. O’Sullivan, R.J.; Kubicek, S.; Schreiber, S.L.; Karlseder, J. Reduced histone biosynthesis and chromatin changes arising from a damage signal at telomeres. Nat. Struct. Mol. Biol. 2010, 17, 1218–1225.
    10. Lee, J.-H.; Kim, E.W.; Croteau, D.L.; Bohr, V.A. Heterochromatin: An epigenetic point of view in aging. Exp. Mol. Med. 2020, 52, 1466–1474.
    11. Marzluff, W.F.; Gongidi, P.; Woods, K.R.; Jin, J.; Maltais, L.J. The human and mouse replication-dependent histone genes. Genomics 2002, 80, 487–498.
    12. Henikoff, S.; Smith, M.M. Histone variants and epigenetics. Cold Spring Harb. Perspect. Biol. 2015, 7, a019364.
    13. Buschbeck, M.; Uribesalgo, I.; Wibowo, I.; Rué, P.; Martin, D.; Gutierrez, A.; Morey, L.; Guigó, R.; López-Schier, H.; Di Croce, L. The histone variant macroH2A is an epigenetic regulator of key developmental genes. Nat. Struct. Mol. Biol. 2009, 16, 1074–1079.
    14. Pehrson, J.R.; Fried, V.A. MacroH2A, a core histone containing a large nonhistone region. Science 1992, 257, 1398–1400.
    15. Gaspar-Maia, A.; Qadeer, Z.A.; Hasson, D.; Ratnakumar, K.; Leu, N.A.; Leroy, G.; Liu, S.; Costanzi, C.; Valle-Garcia, D.; Schaniel, C.; et al. MacroH2A histone variants act as a barrier upon reprogramming towards pluripotency. Nat. Commun. 2013, 4, 1565.
    16. Kreiling, J.A.; Tamamori-Adachi, M.; Sexton, A.N.; Jeyapalan, J.C.; Munoz-Najar, U.; Peterson, A.L.; Manivannan, J.; Rogers, E.S.; Pchelintsev, N.A.; Adams, P.D.; et al. Age-associated increase in heterochromatic marks in murine and primate tissues. Aging Cell 2011, 10, 292–304.
    17. Tvardovskiy, A.; Schwämmle, V.; Kempf, S.J.; Rogowska-Wrzesinska, A.; Jensen, O.N. Accumulation of histone variant H3.3 with age is associated with profound changes in the histone methylation landscape. Nucleic Acids Res. 2017, 45, 9272–9289.
    18. Piazzesi, A.; Papić, D.; Bertan, F.; Salomoni, P.; Nicotera, P.; Bano, D. Replication-Independent Histone Variant H3.3 Controls Animal Lifespan through the Regulation of Pro-longevity Transcriptional Programs. Cell Rep. 2016, 17, 987–996.
    19. Maze, I.; Wenderski, W.; Noh, K.-M.; Bagot, R.C.; Tzavaras, N.; Purushothaman, I.; Elsässer, S.J.; Guo, Y.; Ionete, C.; Hurd, Y.L.; et al. Critical Role of Histone Turnover in Neuronal Transcription and Plasticity. Neuron 2015, 87, 77–94.
    20. Balajee, A.S.; Geard, C.R. Replication protein A and gamma-H2AX foci assembly is triggered by cellular response to DNA double-strand breaks. Exp. Cell Res. 2004, 300, 320–334.
    21. Sharma, A.; Singh, K.; Almasan, A. Histone H2AX phosphorylation: A marker for DNA damage. Methods Mol. Biol. 2012, 920, 613–626.
    22. Jin, B.; Li, Y.; Robertson, K.D. DNA methylation: Superior or subordinate in the epigenetic hierarchy? Genes Cancer 2011, 2, 607–617.
    23. Auclair, G.; Weber, M. Mechanisms of DNA methylation and demethylation in mammals. Biochimie 2012, 94, 2202–2211.
    24. Hyun, J.; Jung, Y. DNA Methylation in Nonalcoholic Fatty Liver Disease. Int. J. Mol. Sci. 2020, 21, 8138.
    25. Lister, R.; Pelizzola, M.; Dowen, R.H.; Hawkins, R.D.; Hon, G.; Tonti-Filippini, J.; Nery, J.R.; Lee, L.; Ye, Z.; Ngo, Q.-M.; et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature 2009, 462, 315–322.
    26. Schübeler, D. Function and information content of DNA methylation. Nature 2015, 517, 321–326.
    27. He, Y.-F.; Li, B.-Z.; Li, Z.; Liu, P.; Wang, Y.; Tang, Q.; Ding, J.; Jia, Y.; Chen, Z.; Li, L.; et al. Tet-mediated formation of 5-carboxylcytosine and its excision by TDG in mammalian DNA. Science 2011, 333, 1303–1307.
    28. Ito, S.; Shen, L.; Dai, Q.; Wu, S.C.; Collins, L.B.; Swenberg, J.A.; He, C.; Zhang, Y. Tet proteins can convert 5-methylcytosine to 5-formylcytosine and 5-carboxylcytosine. Science 2011, 333, 1300–1303.
    29. Wu, H.; Zhang, Y. Reversing DNA methylation: Mechanisms, genomics, and biological functions. Cell 2014, 156, 45–68.
    30. Rasmussen, K.D.; Helin, K. Role of TET enzymes in DNA methylation, development, and cancer. Genes Dev. 2016, 30, 733–750.
    31. Hashimoto, H.; Liu, Y.; Upadhyay, A.K.; Chang, Y.; Howerton, S.B.; Vertino, P.M.; Zhang, X.; Cheng, X. Recognition and potential mechanisms for replication and erasure of cytosine hydroxymethylation. Nucleic Acids Res. 2012, 40, 4841–4849.
    32. Weinhouse, C.; Truong, L.; Meyer, J.N.; Allard, P. Caenorhabditis elegans as an emerging model system in environmental epigenetics. Environ. Mol. Mutagen. 2018, 59, 560–575.
    33. Greer, E.L.; Blanco, M.A.; Gu, L.; Sendinc, E.; Liu, J.; Aristizábal-Corrales, D.; Hsu, C.-H.; Aravind, L.; He, C.; Shi, Y. DNA Methylation on N6-Adenine in C. elegans. Cell 2015, 161, 868–878.
    34. Deshmukh, S.; Ponnaluri, V.C.; Dai, N.; Pradhan, S.; Deobagkar, D. Levels of DNA cytosine methylation in the Drosophila genome. PeerJ 2018, 6, e5119.
    35. Day, K.; Waite, L.L.; Thalacker-Mercer, A.; West, A.; Bamman, M.M.; Brooks, J.D.; Myers, R.M.; Absher, D. Differential DNA methylation with age displays both common and dynamic features across human tissues that are influenced by CpG landscape. Genome Biol. 2013, 14, R102.
    36. Horvath, S. DNA methylation age of human tissues and cell types. Genome Biol. 2013, 14, R115.
    37. Horvath, S. Erratum to: DNA methylation age of human tissues and cell types. Genome Biol. 2015, 16, 96.
    38. Jylhävä, J.; Pedersen, N.L.; Hägg, S. Biological Age Predictors. EBioMedicine 2017, 21, 29–36.
    39. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. Cell 2000, 100, 57–70.
    40. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674.
    41. Flavahan, W.A.; Gaskell, E.; Bernstein, B.E. Epigenetic plasticity and the hallmarks of cancer. Science 2017, 357, eaal2380.
    42. Nebbioso, A.; Tambaro, F.P.; Dell’Aversana, C.; Altucci, L. Cancer epigenetics: Moving forward. PLoS Genet. 2018, 14, e1007362.
    43. Baylin, S.B.; Jones, P.A. A decade of exploring the cancer epigenome—Biological and translational implications. Nat. Rev. Cancer 2011, 11, 726–734.
    44. Franceschi, C.; Bonafè, M.; Valensin, S.; Olivieri, F.; de Luca, M.; Ottaviani, E.; de Benedictis, G. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann. N. Y. Acad. Sci. 2000, 908, 244–254.
    45. Fulop, T.; Larbi, A.; Dupuis, G.; Le Page, A.; Frost, E.H.; Cohen, A.A.; Witkowski, J.M.; Franceschi, C. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: Friends or Foes? Front. Immunol. 2017, 8, 1960.
    46. Sullivan, K.E.; Reddy, A.B.M.; Dietzmann, K.; Suriano, A.R.; Kocieda, V.P.; Stewart, M.; Bhatia, M. Epigenetic regulation of tumor necrosis factor alpha. Mol. Cell. Biol. 2007, 27, 5147–5160.
    47. Ray, D.; Yung, R. Immune Senescence, Epigenetics and Autoimmunity. Clin. Immunol. 2018, 196, 59–63.
    48. Wang, H.; Feng, H.; Sun, J.; Zhou, Y.; Zhu, G.; Wu, S.; Bao, W. Age-associated changes in DNA methylation and expression of the TNFα gene in pigs. Genes Genet. Syst. 2018, 93, 191–198.
    49. Tilstra, J.S.; Clauson, C.L.; Niedernhofer, L.J.; Robbins, P.D. NF-κB in Aging and Disease. Aging Dis. 2011, 2, 449–465.
    50. Li, Y.; Reddy, M.A.; Miao, F.; Shanmugam, N.; Yee, J.-K.; Hawkins, D.; Ren, B.; Natarajan, R. Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. J. Biol. Chem. 2008, 283, 26771–26781.
    51. Wang, Y.; Wang, L.; Wen, X.; Hao, D.; Zhang, N.; He, G.; Jiang, X. NF-κB signaling in skin aging. Mech. Ageing Dev. 2019, 184, 111160.
    52. Choi, Y.J.; Moon, K.M.; Chung, K.W.; Jeong, J.W.; Park, D.; Kim, D.H.; Yu, B.P.; Chung, H.Y. The underlying mechanism of proinflammatory NF-κB activation by the mTORC2/Akt/IKKα pathway during skin aging. Oncotarget 2016, 7, 52685–52694.
    53. Johnsen, S.A. The enigmatic role of H2Bub1 in cancer. FEBS Lett. 2012, 586, 1592–1601.
    54. Tarcic, O.; Pateras, I.S.; Cooks, T.; Shema, E.; Kanterman, J.; Ashkenazi, H.; Boocholez, H.; Hubert, A.; Rotkopf, R.; Baniyash, M.; et al. RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Rep. 2016, 14, 1462–1476.
    55. Kosinsky, R.L.; Chua, R.L.; Qui, M.; Saul, D.; Mehlich, D.; Ströbel, P.; Schildhaus, H.-U.; Wegwitz, F.; Faubion, W.A.; Johnsen, S.A. Loss of RNF40 Decreases NF-κB Activity in Colorectal Cancer Cells and Reduces Colitis Burden in Mice. J. Crohns. Colitis 2019, 13, 362–373.
    56. Yang, Z.-H.; Dang, Y.-Q.; Ji, G. Role of epigenetics in transformation of inflammation into colorectal cancer. World J. Gastroenterol. 2019, 25, 2863–2877.
    57. Yuan, J.; Zhang, F.; Niu, R. Multiple regulation pathways and pivotal biological functions of STAT3 in cancer. Sci. Rep. 2015, 5, 17663.
    58. Zimmers, T.A.; Fishel, M.L.; Bonetto, A. STAT3 in the Systemic Inflammation of Cancer Cachexia. Semin. Cell Dev. Biol. 2016, 54, 28–41.
    59. Takeshima, H.; Niwa, T.; Yamashita, S.; Takamura-Enya, T.; Iida, N.; Wakabayashi, M.; Nanjo, S.; Abe, M.; Sugiyama, T.; Kim, Y.-J.; et al. TET repression and increased DNMT activity synergistically induce aberrant DNA methylation. J. Clin. Investig. 2020, 130, 5370–5379.
    60. Jiang, S.; Yan, W.; Wang, S.E.; Baltimore, D. Dual mechanisms of posttranscriptional regulation of Tet2 by Let-7 microRNA in macrophages. Proc. Natl. Acad. Sci. USA 2019, 116, 12416–12421.
    61. Horvath, S.; Erhart, W.; Brosch, M.; Ammerpohl, O.; von Schönfels, W.; Ahrens, M.; Heits, N.; Bell, J.T.; Tsai, P.-C.; Spector, T.D.; et al. Obesity accelerates epigenetic aging of human liver. Proc. Natl. Acad. Sci. USA 2014, 111, 15538–15543.
    62. Hanson, B.M.; Tao, X.; Zhan, Y.; Jenkins, T.G.; Morin, S.J.; Scott, R.T.; Seli, E.U. Young women with poor ovarian response exhibit epigenetic age acceleration based on evaluation of white blood cells using a DNA methylation-derived age prediction model. Hum. Reprod. 2020, 35, 2579–2588.
    63. Morin, S.J.; Tao, X.; Marin, D.; Zhan, Y.; Landis, J.; Bedard, J.; Scott, R.T.; Seli, E. DNA methylation-based age prediction and telomere length in white blood cells and cumulus cells of infertile women with normal or poor response to ovarian stimulation. Aging (Albany NY) 2018, 10, 3761–3773.
    64. Marioni, R.E.; Shah, S.; McRae, A.F.; Chen, B.H.; Colicino, E.; Harris, S.E.; Gibson, J.; Henders, A.K.; Redmond, P.; Cox, S.R.; et al. DNA methylation age of blood predicts all-cause mortality in later life. Genome Biol. 2015, 16, 25.
    65. Johnson, P.L.F.; Goronzy, J.J.; Antia, R. A population biological approach to understanding the maintenance and loss of the T-cell repertoire during aging. Immunology 2014, 142, 167–175.
    66. Stevenson, A.J.; McCartney, D.L.; Harris, S.E.; Taylor, A.M.; Redmond, P.; Starr, J.M.; Zhang, Q.; McRae, A.F.; Wray, N.R.; Spires-Jones, T.L.; et al. Trajectories of inflammatory biomarkers over the eighth decade and their associations with immune cell profiles and epigenetic ageing. Clin. Epigenetics 2018, 10, 159.
    67. Quinn, K.M.; Fox, A.; Harland, K.L.; Russ, B.E.; Li, J.; Nguyen, T.H.O.; Loh, L.; Olshanksy, M.; Naeem, H.; Tsyganov, K.; et al. Age-Related Decline in Primary CD8+ T Cell Responses Is Associated with the Development of Senescence in Virtual Memory CD8+ T Cells. Cell Rep. 2018, 23, 3512–3524.
    68. Lau, E.Y.M.; Carroll, E.C.; Callender, L.A.; Hood, G.A.; Berryman, V.; Pattrick, M.; Finer, S.; Hitman, G.A.; Ackland, G.L.; Henson, S.M. Type 2 diabetes is associated with the accumulation of senescent T cells. Clin. Exp. Immunol. 2019, 197, 205–213.
    69. Bektas, A.; Schurman, S.H.; Sen, R.; Ferrucci, L. Human T cell immunosenescence and inflammation in aging. J. Leukoc. Biol. 2017, 102, 977–988.
    70. Surace, A.E.A.; Hedrich, C.M. The Role of Epigenetics in Autoimmune/Inflammatory Disease. Front. Immunol. 2019, 10, 1525.
    71. Mikami, N.; Kawakami, R.; Sakaguchi, S. New Treg cell-based therapies of autoimmune diseases: Towards antigen-specific immune suppression. Curr. Opin. Immunol. 2020, 67, 36–41.
    72. Dozmorov, M.G.; Coit, P.; Maksimowicz-McKinnon, K.; Sawalha, A.H. Age-associated DNA methylation changes in naive CD4+ T cells suggest an evolving autoimmune epigenotype in aging T cells. Epigenomics 2017, 9, 429–445.
    73. Hofmann, S.R.; Kubasch, A.S.; Ioannidis, C.; Rösen-Wolff, A.; Girschick, H.J.; Morbach, H.; Hedrich, C.M. Altered expression of IL-10 family cytokines in monocytes from CRMO patients result in enhanced IL-1β expression and release. Clin. Immunol. 2015, 161, 300–307.
    74. Wu, Z.-X.; Cao, L.; Li, X.-W.; Jiang, W.; Li, X.-Y.; Xu, J.; Wang, F.; Chen, G.-H. Accelerated Deficits of Spatial Learning and Memory Resulting From Prenatal Inflammatory Insult Are Correlated With Abnormal Phosphorylation and Methylation of Histone 3 in CD-1 Mice. Front. Aging Neurosci. 2019, 11.
    75. Cakouros, D.; Gronthos, S. Epigenetic Regulators of Mesenchymal Stem/Stromal Cell Lineage Determination. Curr. Osteoporos. Rep. 2020, 18, 597–605.
    76. Sepulveda, H.; Villagra, A.; Montecino, M. Tet-Mediated DNA Demethylation Is Required for SWI/SNF-Dependent Chromatin Remodeling and Histone-Modifying Activities That Trigger Expression of the Sp7 Osteoblast Master Gene during Mesenchymal Lineage Commitment. Mol. Cell. Biol. 2017, 37, e00177-17.
    77. Wang, R.; Wang, Y.; Zhu, L.; Liu, Y.; Li, W. Epigenetic Regulation in Mesenchymal Stem Cell Aging and Differentiation and Osteoporosis. Stem Cells Int. 2020, 2020, 1–17.
    78. Bork, S.; Pfister, S.; Witt, H.; Horn, P.; Korn, B.; Ho, A.D.; Wagner, W. DNA methylation pattern changes upon long-term culture and aging of human mesenchymal stromal cells. Aging Cell 2010, 9, 54–63.
    79. Cakouros, D.; Hemming, S.; Gronthos, K.; Liu, R.; Zannettino, A.; Shi, S.; Gronthos, S. Specific functions of TET1 and TET2 in regulating mesenchymal cell lineage determination. Epigenetics Chromatin 2019, 12, 3.
    80. Yang, R.; Yu, T.; Kou, X.; Gao, X.; Chen, C.; Liu, D.; Zhou, Y.; Shi, S. Tet1 and Tet2 maintain mesenchymal stem cell homeostasis via demethylation of the P2rX7 promoter. Nat. Commun. 2018, 9, 2143.
    81. Ko, N.-Y.; Chen, L.-R.; Chen, K.-H. The Role of Micro RNA and Long-Non-Coding RNA in Osteoporosis. Int. J. Mol. Sci. 2020, 21, 4886.
    82. Gontier, G.; Iyer, M.; Shea, J.M.; Bieri, G.; Wheatley, E.G.; Ramalho-Santos, M.; Villeda, S.A. Tet2 Rescues Age-Related Regenerative Decline and Enhances Cognitive Function in the Adult Mouse Brain. Cell Rep. 2018, 22, 1974–1981.
    83. Ren, J.; Huang, D.; Li, R.; Wang, W.; Zhou, C. Control of mesenchymal stem cell biology by histone modifications. Cell Biosci. 2020, 10, 1–15.
    84. Jing, H.; Liao, L.; An, Y.; Su, X.; Liu, S.; Shuai, Y.; Zhang, X.; Jin, Y. Suppression of EZH2 Prevents the Shift of Osteoporotic MSC Fate to Adipocyte and Enhances Bone Formation During Osteoporosis. Mol. Ther. 2016, 24, 217–229.
    85. Ma, J.; Lin, X.; Chen, C.; Li, S.; Zhang, S.; Chen, Z.; Li, D.; Zhao, F.; Yang, C.; Yin, C.; et al. Circulating miR-181c-5p and miR-497-5p Are Potential Biomarkers for Prognosis and Diagnosis of Osteoporosis. J. Clin. Endocrinol. Metab. 2020, 105, 1445–1460.
    86. Bone, H.G.; Wagman, R.B.; Brandi, M.L.; Brown, J.P.; Chapurlat, R.; Cummings, S.R.; Czerwiński, E.; Fahrleitner-Pammer, A.; Kendler, D.L.; Lippuner, K.; et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: Results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017, 5, 513–523.
    87. de Nigris, F.; Ruosi, C.; Colella, G.; Napoli, C. Epigenetic therapies of osteoporosis. Bone 2020, 142, 115680.